Galapagos « Terug naar discussie overzicht

Galapagos augustus 2017

3.476 Posts, Pagina: « 1 2 3 4 5 6 ... 87 88 89 90 91 92 93 94 95 96 97 ... 170 171 172 173 174 » | Laatste
adritromp
0
quote:

Gala-diner schreef op 11 augustus 2017 16:20:

[...]

Ik verwacht dat meerdere professionele partijen na de prima resultaten van 1690 hun posities aan het uitbreiden zijn, buitenkansje voor ze op dit koersnivo.
Misschien ook wel ja, af en toe gaat de stofzuiger weer even aan en kopen ze alles op. Koers schiet dan omhoog, mooi om te zien. Als ze dit volgende week ook blijven doen kan het hard gaan
Gala-diner
0
quote:

BLOO7 schreef op 11 augustus 2017 16:24:

[...]

Gisteren werd Galapagos pas echt internationaal bekend op een rode beursdag.
We gaan volgens mij met rasse schreden naar een ATH (schommelingen inbegrepen).
Fantastische ontwikkelingen bij Galapagos en ook nog eens 1,3 miljard in kas, logisch dat we binnenkort een nieuw ATH gaan noteren.
En als gevolg koersdoel verhogingen van analisten.
avantiavanti
6
Gala-diner
0
quote:

avantiavanti schreef op 11 augustus 2017 16:33:

Stifel update 11 augustus

Mooie afsluiter voor deze week.

We are upgrading Galapagos to Buy from Hold and increasing our TP to $101 from $83 based on: 1) what we view as clearly positive early P2 POC results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis (IPF) – which compels us to include the drug in our model at a very reasonable 10% probability of success (POS), and; 2) reduced downside risk associated
with Galapagos’ CF triple combo - as we believe recently announced delay of P2 launch and positive Vertex triple results have brought Street views in line with our 15% POS. In addition, positive GLPG1690 results increase our confidence in the company’s target discovery platform.
With ~$1.5B in cash, Galapagos remains well-positioned to capitalize on its internal discovery
efforts, in our view.
MrMarket
0
In het orderboek dat ik sta worden er telkens duizenden stukjes op 71 aangeboden, al een keer of 5 nu. Hopelijk zijn we er nu doorheen :D
Gala-diner
0
quote:

Gala-diner schreef op 11 augustus 2017 16:38:

[...]
We are upgrading Galapagos to Buy from Hold and increasing our TP to $101 from $83 based on: 1) what we view as clearly positive early P2 POC results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis (IPF) – which compels us to include the drug in our model at a very reasonable 10% probability of success (POS), and; 2) reduced downside risk associated
with Galapagos’ CF triple combo - as we believe recently announced delay of P2 launch and positive Vertex triple results have brought Street views in line with our 15% POS. In addition, positive GLPG1690 results increase our confidence in the company’s target discovery platform.
With ~$1.5B in cash, Galapagos remains well-positioned to capitalize on its internal discovery
efforts, in our view.
De volgende boost voor de koers zit er binnenkort ook nog aan te komen.
P1b MOR106 (anti-IL-17c mAb) results in atopic dermatitis expected 3Q17: The study is being conducted in two parts: a SAD and MAD. The SAD includes seven cohorts (n=42) of healthy males receiving IV MOR106 over four weeks vs. placebo (n=14). The MAD portion includes three cohorts of subjects with moderate to severe atopic dermatitis (n=18) dosed by IV over four weeks vs. placebo (n=6). The primary and secondary objectives include safety, tolerability, and PK. Exploratory objectives include Eczema Area & Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), Investigator Global Assessment (IGA), Dermatology Quality of Life Index (DLQI), and effect on Thymus & Activation-Regulated Chemokine (TARC).
MOR106 is key potential driver: POC results due in 3Q17 provide significant optionality, in our view, as positive data would add a significant new leg to the story that we do not currently include in our model.
BLOO7
0
quote:

Gala-diner schreef op 11 augustus 2017 16:38:

[...]
We are upgrading Galapagos to Buy from Hold and increasing our TP to $101 from $83 based on: 1) what we view as clearly positive early P2 POC results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis (IPF) – which compels us to include the drug in our model at a very reasonable 10% probability of success (POS), and; 2) reduced downside risk associated
with Galapagos’ CF triple combo - as we believe recently announced delay of P2 launch and positive Vertex triple results have brought Street views in line with our 15% POS. In addition, positive GLPG1690 results increase our confidence in the company’s target discovery platform.
With ~$1.5B in cash, Galapagos remains well-positioned to capitalize on its internal discovery
efforts, in our view.
Ik vond deze mooier:
www.trivano.com/aandeel/advies-jeffer...

hm, 110,00 EUR
C200
0
quote:

BeursBonobo schreef op 11 augustus 2017 16:41:

In het orderboek dat ik sta worden er telkens duizenden stukjes op 71 aangeboden, al een keer of 5 nu. Hopelijk zijn we er nu doorheen :D
er staan er weer 6694
C200
0
quote:

C200 schreef op 11 augustus 2017 16:45:

[...]

er staan er weer 6694
En weer weg. Het is net PacMan haphaphap
bokie2
0
C200
0
voda
1
quote:

C200 schreef op 11 augustus 2017 16:52:

[...]

En weer weg. Het is net PacMan haphaphap
Schitterende game & geluiden. :-)

www.pacmangame.nl/spelletjes/pacman-c...
[verwijderd]
0
quote:

bokie2 schreef op 11 augustus 2017 16:57:

koers van Amerika van galapagos waar kun je die volgen......?
Loopt vanaf 15.30 uur omgerekend exact gelijk met Europa..
[verwijderd]
0
3.476 Posts, Pagina: « 1 2 3 4 5 6 ... 87 88 89 90 91 92 93 94 95 96 97 ... 170 171 172 173 174 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 10 mei 2024 17:35
Koers 26,660
Verschil 0,000 (0,00%)
Hoog 26,920
Laag 26,660
Volume 44.236
Volume gemiddeld 85.274
Volume gisteren 44.236

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront